Clinical Trial Update: Tipifarnib in Treating Patients With Myelodysplastic Syndromes [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update showing completion of a tipifarnib study in patients with myelodysplastic syndromes and related myeloid disorders.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Anemia with Excess Blasts
• Anemia with Excess Blasts in Transformation
• Anemia with Ring Sideroblasts
• Cytopenia with Multilineage Dysplasia
• De Novo Myelodysplastic Syndromes
• Myelomonocytic Leukemia
• Previously Treated Myelodysplastic Syndromes

Drugs mentioned

• Tipifarnib (tipifarnib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes | Phase 1 | Status: COMPLETED